AU Patent

AU2021282393A1 — Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof

Assigned to Impax Laboratories LLC · Expires 2021-12-23 · 4y expired

What this patent protects

The invention provides a controlled release oral formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levadopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated…

USPTO Abstract

The invention provides a controlled release oral formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levadopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer and (b) a decarboxylase inhibitor component.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021282393A1
Jurisdiction
AU
Classification
—
Expires
2021-12-23
Drug substance claim
No
Drug product claim
No
Assignee
Impax Laboratories LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.